Benay Taub Lung Cancer Research Act
Summary
HR6319 is an early-stage bill that establishes a Lung Cancer Task Force within NIH to study research disparities, funding levels, and screenings. It authorizes no funding and creates no direct revenue or cost impact on any publicly traded company. No market action is justified at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Zero funding or spending authorized — no money trail for investors
- 2.Merely establishes a study task force with no binding recommendations
- 3.Early procedural stage with no committee action since Nov 2025
- 4.No identified tickers — no causal chain from bill text to any public company revenue
Market Implications
No market implications. HR6319 is a study-authorization bill with zero appropriations. It does not change the competitive dynamics, revenue outlook, or regulatory burden for any publicly traded company in lung cancer diagnostics, therapeutics, or screening. Retail investors should ignore this legislation until and unless it advances to a funding stage.
Full Analysis
- On November 28, 2025, Rep. Gottheimer (D-NJ) introduced HR6319, the Benay Taub Lung Cancer Research Act. It was immediately referred to the House Committee on Energy and Commerce and has had no further action since referral. The bill is in its earliest legislative stage with zero committee hearings, markups, or votes. 2) The bill text creates a task force within NIH to examine lung cancer research disparities relative to other diseases, federal funding levels, and screening rates. It does not authorize or appropriate any dollar amount. The task force must report findings and recommendations to Congress within 180 days of enactment. There is no procurement mandate, no grant program, no tax credit, and no regulatory requirement directed at private companies. 3) Without funding or any binding directive, there are no structural winners or losers in publicly traded equities. Companies with exposure to lung cancer diagnostics, therapeutics, or screening technology — such as $LLY (oncology pipeline), $JNJ (lung cancer drugs), $BMY (Opdivo), $MRK (Keytruda), or screening firms like $ILMN (genomic sequencing) — have zero direct revenue channel from this procedural bill. 4) The bill has only 4 cosponsors, all junior members, and sits in the Commerce Committee. No companion bill exists in the Senate. Legislative velocity is minimal. 5) Remaining steps: committee consideration, potential markup, House vote, Senate introduction/passage, presidential signature. Given the procedural nature and zero funding authorization, this bill has effectively no timeline pressure or market relevance for at least 12-18 months, if ever.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Protecting Americans from Unsafe Drugs Act of 2026
American Innovation and R&D Competitiveness Act of 2025
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
Most Favored Patient Act of 2026
Lowering Drug Costs for American Families Act
Skinny Labels, Big Savings Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.